Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
MIRA Pharmaceuticals is a pre-revenue clinical-stage biopharmaceutical company focused on developing novel oral ketamine-based therapies for neuropsychiatric disorders and neurodegenerative diseases. The company operates with minimal infrastructure, outsourcing R&D to contract research organizations, and is entirely dependent on capital markets funding to advance its pipeline through FDA clinical trials. With zero revenue, negative cash flow of approximately $3-5M annually, and a current ratio above 90, MIRA maintains sufficient liquidity for near-term operations but faces binary clinical trial outcomes that will determine survival.
MIRA operates a capital-intensive, binary-outcome business model typical of clinical-stage biotechs. The company raises equity capital through public offerings and warrants to fund clinical trials conducted by CROs. Value creation depends entirely on successfully navigating Phase I/II/III trials, obtaining FDA approval, and either commercializing products independently or licensing intellectual property to larger pharmaceutical companies. With oral ketamine formulations targeting CNS disorders, MIRA competes in a crowded space where differentiation requires demonstrating superior efficacy, safety, or pharmacokinetics versus existing IV ketamine and esketamine nasal spray (Spravato). The company has no pricing power until post-approval and faces 8-12 year development timelines with 90%+ failure rates industry-wide.
Clinical trial data readouts and FDA milestone announcements (Phase advancement, safety signals, efficacy endpoints)
Capital raises and dilution events (equity offerings, warrant exercises that expand share count)
Partnership announcements or licensing deals with larger pharmaceutical companies
Competitive developments in ketamine-based therapies or alternative CNS disorder treatments
Cash runway updates and quarterly burn rate disclosures
Binary clinical trial outcomes with 90%+ industry failure rates - single negative Phase II/III readout could render equity worthless
Regulatory pathway uncertainty for novel ketamine formulations given existing approved products (esketamine) and off-label IV ketamine use
Intellectual property challenges in crowded ketamine therapy space - patent protection may be narrow or face validity challenges
Capital markets dependency with no revenue generation - extended bear markets or biotech sector dislocation could eliminate funding access
Johnson & Johnson's Spravato (esketamine nasal spray) already approved for treatment-resistant depression with established market presence
Generic IV ketamine widely available off-label at significantly lower cost than potential oral formulations
Larger pharmaceutical companies (Biogen, Eli Lilly, Roche) developing competing CNS therapies with vastly superior resources
Oral bioavailability and pharmacokinetic challenges may limit commercial viability versus existing delivery methods
Extreme negative ROE (-978.7%) and ROA (-372.3%) reflect accumulated losses and equity destruction - typical for pre-revenue stage but unsustainable long-term
Cash burn of $3-5M annually with current ratio of 90.53 suggests 2-3 year runway at current burn, but Phase III trials would require significant additional capital
Dilution risk from future equity raises - micro-cap structure ($0.0B market cap per data) means small offerings cause massive percentage dilution
No debt capacity or non-dilutive financing options given lack of revenue or tangible assets
low - Pre-revenue biotechs are largely insulated from GDP fluctuations as they generate no sales. However, economic downturns indirectly impact access to capital markets, making equity raises more difficult or dilutive. Investor risk appetite for speculative biotech declines during recessions, compressing valuations and increasing cost of capital. Clinical trial timelines are unaffected by economic cycles, but funding constraints may force trial delays.
Rising interest rates negatively impact MIRA through multiple channels: (1) Higher discount rates compress NPV of distant future cash flows, disproportionately affecting long-duration assets like clinical-stage pipelines; (2) Risk-free rate competition makes speculative biotech less attractive versus bonds; (3) Reduced investor appetite for unprofitable growth companies during tightening cycles. MIRA carries no debt (Debt/Equity: 0.00), so direct financing cost impact is minimal, but equity valuation multiples contract significantly as 10-year Treasury yields rise above 4-5%.
Minimal direct credit exposure. MIRA operates debt-free and funds operations through equity. However, credit market conditions indirectly affect biotech sector sentiment and institutional investor allocation to high-risk/high-reward assets. Widening high-yield spreads typically correlate with biotech underperformance as risk-off sentiment dominates.
momentum/speculative - MIRA attracts high-risk tolerance investors seeking asymmetric payoffs from binary clinical events. Typical shareholders include retail traders, biotech-focused hedge funds, and venture-style investors willing to accept total loss probability in exchange for 10-50x upside if trials succeed. Not suitable for value or income investors given zero revenue, negative cash flow, and no dividend. Recent 14.9% one-year return despite -20.5% three-month decline reflects extreme volatility around news catalysts.
high - Clinical-stage micro-cap biotechs exhibit 80-150% annualized volatility. Single-day moves of 30-50% common around trial data releases. Beta likely exceeds 2.0 relative to broader market. Illiquid trading (micro-cap) amplifies price swings. Options market typically prices implied volatility at 100%+ for near-term expirations around known catalysts.
